US-based immuno-oncology company Formula Pharmaceuticals has initiated a Phase I/IIa clinical trial of allogeneic, cytokine-induced killer (CIK), cell-based chimeric antigen receptor (CAR) cancer immunotherapy for acute lymphoblastic leukaemia (ALL).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The CIK CAR technology is currently being developed to activate functionality of T-cells and natural killer cells within one effector cell population obtained from healthy donor or cord blood.

Designed to enrol both paediatric and adult patients with relapsed or refractory ALL, the open-label, dose-escalating Phase I/IIa trial will assess the safety, pharmacokinetics (PK) and anti-tumour activity of the modified allogeneic CIK cells.

Formula Pharmaceuticals president and CEO Maurits Geerlings said: “This clinical trial is the first to evaluate non-virally transfected, allogeneic CIK CAR in patients with cancer and is designed to demonstrate important clinical proof-of-concept for our entire platform.”

"We look forward to expanding our close collaboration with Formula into additional haematologic cancer applications."

Funded by non-profit scientific institution Fondazione Matilde Tettamanti, the trial is performed at the MBBM Foundation / San Gerardo Hospital in Monza and the Azienda Ospedaliera Papa Giovanni XXIII in Bergamo, Italy.

Fondazione Matilde Tettamanti scientific director professor Andrea Biondi said: “We are very proud to have led the CIK CAR programme from the bench to the clinic and look forward to demonstrating the therapeutic potential of this platform for patients with persistent unmet need.

“We look forward to expanding our close collaboration with Formula into additional haematologic cancer applications.”

Based on its allogeneic CIK CAR technology platform, Formula is developing CAR immunotherapies for different haematologic and solid tumour indications.

Image: Acute lymphoblastic leukaemia. Photo: courtesy of VashiDonsk/English Wikipedia.